Otto Rorstad

Summary

Affiliation: University of Calgary
Country: Canada

Publications

  1. ncbi request reprint Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract
    Otto Rorstad
    Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    J Surg Oncol 89:151-60. 2005
  2. doi request reprint Role of imaging in the preoperative staging of small bowel neuroendocrine tumors
    Anthony J Chambers
    Department of Surgery, Division of Surgical Oncology, University of Calgary and the Tom Baker Cancer Centre, Calgary, Alberta, Canada
    J Am Coll Surg 211:620-7. 2010
  3. doi request reprint The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors
    Anthony J Chambers
    University of Calgary, Tom Baker Cancer Centre, Calgary, Alberta, Canada
    Surgery 144:645-51; discussion 651-3. 2008
  4. doi request reprint Cognitive impairment associated with carcinoid syndrome
    Janice L Pasieka
    Department of Surgery, Division of General Surgery and Surgical Oncology, University of Calgary and Tom Baker Cancer Center, Calgary, Alberta, Canada Department of Medicine, Division of Endocrinology, University of Calgary and Tom Baker Cancer Center, Calgary, Alberta, Canada and Department of Psychology, Foothills Hospital, Calgary, Alberta, Canada
    Ann Surg 259:355-9. 2014
  5. doi request reprint Impairment of cognitive function reported by patients suffering from carcinoid syndrome
    Anthony J Chambers
    Divisions of Surgical Oncology and General Surgery, Department of Surgery, University of Calgary and Tom Baker Cancer Centre, Calgary, AB, T2N 2T9, Canada
    World J Surg 34:1356-60. 2010
  6. ncbi request reprint The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms
    Janice L Pasieka
    Division of General Surgery, Department of Surgery, North Tower, University of Calgary and Tom Baker Cancer Center, 1403 29th Street NW, Calgary, Alberta, Canada T2N 2T9
    Surgery 136:1218-26. 2004
  7. ncbi request reprint 131I-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumors
    Mark S Sywak
    Royal North Shore Hospital, St Leonards, New South Wales, Australia
    World J Surg 28:1157-62. 2004

Collaborators

Detail Information

Publications7

  1. ncbi request reprint Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract
    Otto Rorstad
    Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    J Surg Oncol 89:151-60. 2005
    ..Adverse clinical indicators are the malignant carcinoid syndrome, carcinoid heart disease, and high concentrations of the tumor markers, urinary 5-HIAA and plasma chromogranin A...
  2. doi request reprint Role of imaging in the preoperative staging of small bowel neuroendocrine tumors
    Anthony J Chambers
    Department of Surgery, Division of Surgical Oncology, University of Calgary and the Tom Baker Cancer Centre, Calgary, Alberta, Canada
    J Am Coll Surg 211:620-7. 2010
    ..The purpose of this study was to assess the accuracy of preoperative imaging compared with operative findings in the staging of small bowel NET...
  3. doi request reprint The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors
    Anthony J Chambers
    University of Calgary, Tom Baker Cancer Centre, Calgary, Alberta, Canada
    Surgery 144:645-51; discussion 651-3. 2008
    ..The purpose of this study was to assess whether aggressive surgical intervention of metastatic NETs provides effective palliation from these symptoms...
  4. doi request reprint Cognitive impairment associated with carcinoid syndrome
    Janice L Pasieka
    Department of Surgery, Division of General Surgery and Surgical Oncology, University of Calgary and Tom Baker Cancer Center, Calgary, Alberta, Canada Department of Medicine, Division of Endocrinology, University of Calgary and Tom Baker Cancer Center, Calgary, Alberta, Canada and Department of Psychology, Foothills Hospital, Calgary, Alberta, Canada
    Ann Surg 259:355-9. 2014
    ..To evaluate the cognitive performance of patients with carcinoid syndrome (CS) compared with population norms and cancer patients with non-neuroendocrine (non-NET) liver metastases...
  5. doi request reprint Impairment of cognitive function reported by patients suffering from carcinoid syndrome
    Anthony J Chambers
    Divisions of Surgical Oncology and General Surgery, Department of Surgery, University of Calgary and Tom Baker Cancer Centre, Calgary, AB, T2N 2T9, Canada
    World J Surg 34:1356-60. 2010
    ..It has been our impression that patients with CS also exhibit features of cognitive impairment. The purpose of this pilot study was to evaluate if symptoms of cognitive impairment were reported by patients with CS...
  6. ncbi request reprint The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms
    Janice L Pasieka
    Division of General Surgery, Department of Surgery, North Tower, University of Calgary and Tom Baker Cancer Center, 1403 29th Street NW, Calgary, Alberta, Canada T2N 2T9
    Surgery 136:1218-26. 2004
    ..Radiolabeled octreotide and metaiodobenzylguanidine (MIBG) have demonstrated limited antitumor effect on neuroendocrine neoplasms (NENs). The purpose of this study was to assess the palliative benefit of radionuclide therapy (RNT) in NENs...
  7. ncbi request reprint 131I-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumors
    Mark S Sywak
    Royal North Shore Hospital, St Leonards, New South Wales, Australia
    World J Surg 28:1157-62. 2004
    ..6 years for group A and 5.0 years for group B. Although retrospective in nature, this study suggests that the addition of 131I-mIBG therapy to the treatment protocol of patients with metastatic midgut carcinoid tumors prolongs survival...